Description
The purpose of this study is to find out how often the researchers can avoid an ALND in women with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have only 1 or 2 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.
Eligibility
Inclusion Criteria
- Female patients aged ≥18 years with biopsy-proven invasive breast cancer
- Patients with cT1 or T2 tumors with palpable ipsilateral mobile adenopathy of level I/II axillary nodes with biopsy-proven nodal metastasis (cN1) who are undergoing upfront surgery
- Patients with tumors of the HR+/HER2- subtype, defined as:
- HR+: Positive for estrogen receptor and/or progesterone receptor staining, indicated by ≥1% immunoreactive tumor nuclei
- HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay
Exclusion Criteria
- Patients with occult primary breast cancer
- Patients with prior ipsilateral breast cancer
- Patients who are pregnant
- Patients with stage IV disease at presentation
- Patients with advanced regional disease (cN2/cN3)
